嵌合型CD25单抗治疗造血干细胞移植术后急性移植物抗宿主病  

Chimeric anti-CD25 monoclonal antibody for treating acute graft-versus-host disease after anogeneic hematopoietic stem cell transplantation

作　　者：王景枝[1] 刘开彦[1] 许兰平[1] 刘代红[1] 陈育红[1] 黄晓军[1] 

机构地区：[1]北京大学人民医院北京大学血液病研究所,100044

出　　处：《中华内科杂志》2008年第11期923-925,共3页Chinese Journal of Internal Medicine

基　　金：基金项目：国家杰出青年科学基金（30725038）

摘　　要：目的研究嵌合型CD25单抗治疗造血干细胞移植术后激素耐药的急性移植物抗宿主病（GVHD）的疗效。方法2005年3月至2007年7月诊断急性GVHD的患者36例，在1～2mg／kg的肾上腺皮质激素治疗无效后，应用静脉注射嵌合型CD25单抗治疗。结果总有效率为83．3％（30／36），其中完全缓解率69．4％（25／36），部分缓解率13．9％（5／36）。单因素分析显示疗效与GVHD分度及配型相合程度相关，与累及器官数量无关。患者生存情况与配型情况、GVHD分度及累及器官数量无关。结论嵌合型CD25单克隆抗体是治疗造血干细胞移植术后肾上腺皮质激素耐药的急性GVHD的有效药物。Objective To investigate the efficacy of chimeric anti-CD25 monoclonal antibody （basiliximab） on acute graft-versus-host disease （GVHD） in patients following allogeneie hematopoietic stem cell transplantation. Methods Thirty-six patients who were suffered from acute GVHD from March 2005 to July 2007 were studied. All of them were treated with steroid first and got no response, then began basiliximab therapy. Results Thirty of 36 patients showed response to basiliximab therapy including 25 complete responses and 5 partial responses. The efficacy was associated with the degree of GVHD and the source of donor. Conclusion Patients suffered from steroid-resistant acute GVHD can be successfully treated with basiliximab.

关 键 词：CD25单抗 移植物抗宿主病 造血于细胞移植 

分 类 号：R686[医药卫生—骨科学]